reglab/housing_qa huggingface dataset:
AR Code § 20-15-2102 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2102. Findings

 It is found and determined by the General Assembly of the State of Arkansas that:   (1) The process of approval for investigational drugs, biological products, and devices in the United States often takes many years;  (2) Patients who have a terminal disease do not have the luxury of waiting until an investigational drug, biological product, or device receives final approval;  (3) The standards of the United States Food and Drug Administration for the use of investigational drugs, biological products, and devices may deny the benefits of potentially life-saving treatments to terminally ill patients;  (4) The State of Arkansas recognizes that patients who have a terminal disease have a fundamental right to attempt to pursue the preservation of their own lives by accessing available investigational drugs, biological products, and devices; and  (5) The use of available investigational drugs, biological products , or devices is a decision that should be made by the patient with a terminal disease in consultation with his or her physician.
AR Code § 20-15-2103 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2103. Definitions

 As used in this subchapter:   (1) “Eligible patient” means a person who meets the requirements of eligibility in § 20-15-2104;  (2) “Investigational drug, biological product, or device” means a drug, biological product, or device that:  (A) Has successfully completed phase I of clinical trials but has not been approved for general use by the United States Food and Drug Administration; and  (B) Remains currently under investigation in a United States Food and Drug Administration clinical trial;    (3) “Physician” means an individual licensed to practice medicine in the State of Arkansas under the Arkansas Medical Practices Act, § 17-95-201 et seq., § 17-95-301 et seq., and § 17-95-401 et seq.; and  (4) “Terminal illness” means an incurable and irreversible condition that without the administration of life-sustaining treatment will, in the opinion of the patient's physician, result in death within a relatively short time.
AR Code § 20-15-2104 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2104. Eligibility

 In order for a patient to access an investigational drug, biological product, or device under this subchapter, a physician must document in the patient's medical record and chart that the patient:   (1) Has a terminal illness;  (2) Has a determination from a qualified physician that the patient has no comparable or satisfactory treatment options approved by the United States Food and Drug Administration available to treat the terminal illness and that the probable risk to the patient from the investigational drug, biological product, or device is not greater than the probable risk from the terminal illness;  (3) Has been unable to participate in a clinical trial for the terminal illness within one hundred (100) miles of the patient's home address or has not been accepted to the clinical trial within one (1) week of the completion of the clinical trial application process;  (4) Has been given a prescription by a physician for an investigational drug, biological product, or device;  (5)  (A) Has given informed consent in writing for the use of the investigational drug, biological product, or device.  (B) If the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian may provide informed consent on the patient's behalf; and    (6) Has received written documentation from a physician that the patient meets the requirements of this subchapter.
AR Code § 20-15-2105 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2105. Availability

 A manufacturer of an investigational drug, biological product, or device may, but is not required to, make its investigational drug, biological product, or device available to eligible patients under this subchapter.
AR Code § 20-15-2106 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2106. Costs — Definition

 (a) A manufacturer of an investigational drug, biological product, or device may:  (1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or  (2)  (A) Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device.  (B) As used in this section, “costs associated with the manufacture of the investigational drug, biological product, or device” means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case.      (b) If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the manufacturer related to the investigational drug, biological product, or device.
AR Code § 20-15-2107 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2107. Insurance coverage

 An insurance company:   (1) May, but is not required to, provide coverage for an investigational drug, biological product, or device; and  (2) Shall not deny coverage for an item or service that is otherwise covered by an insurance contract between the eligible person and an insurance company.
AR Code § 20-15-2108 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2108. Prohibited sanctions

 The recommendation, prescription, treatment, or participation in the treatment of a terminal illness with an investigational drug, biological product, or device shall not permit:   (1) A licensing board to revoke a license, fail to renew a license, or take any other action against a physician's license;  (2) A state agency or licensing board to revoke a license, fail to renew a license, or take any other action against:  (A) A medical professional licensed under state law; or  (B) A hospital licensed under § 20-9-213; or    (3) An action against a hospital's Medicare certification.
AR Code § 20-15-2109 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2109. Remedy

 The counseling, advice, or recommendation by a medical professional who is licensed under state law is not a violation of this subchapter.
AR Code § 20-15-2110 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2110. Immunity

 (a) Except in the case of gross negligence or willful misconduct, a person or entity that manufacturers, imports, distributes, prescribes, dispenses, administers, or is otherwise involved in the care of an eligible patient using an investigational drug, biological product, or device is immune from civil liability for any loss, damage, or injury arising out of, relating to, or resulting from the investigational drug, biological product, or device so long as the person or entity is substantially complying in good faith with this subchapter.  (b) This subchapter does not require a medical professional who is licensed under the laws of this state to counsel, advise, prescribe, dispense, administer, or otherwise be involved in the care of an eligible patient using an investigational drug, biological product, or device.  (c) This subchapter does not require a hospital licensed under § 20-9-213 to provide any service related to an investigational drug, biological product, or device.
AR Code § 20-15-2111 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 21 - Right to Try Act|§ 20-15-2111. Medicaid coverage

 This subchapter does not require the Department of Human Services or the Arkansas Medicaid Program to provide additional coverage for an investigational drug, biological product, or device.
AR Code § 20-15-2201 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 22 - Task Force on Alpha-gal|§ 20-15-2201. Findings — Purpose

 (a) The General Assembly finds:  (1) Alpha-gal allergies are a reaction to galactose-alpha-1, 3-galactose, when the body is overloaded with immunoglobulin E antibodies on contact with the galactose carbohydrate;  (2) Bites from the lone star tick, which transfer this carbohydrate to the victim, have been implicated in the development of this delayed allergic response which is triggered by the consumption of mammalian meat products;  (3) Alpha-gal allergies most often occur in the central and southern states such as Arkansas, where the lone star tick is more prevalent;  (4) A typical allergic reaction to Alpha-gal has a delayed onset, occurring four to eight (4-8) hours after the consumption of mammalian meat products, instead of the typical rapid onset with most food allergies;  (5) Since the reaction to eating mammal meat is delayed by several hours, the proper diagnosis is often missed or the patient is misdiagnosed;  (6) People who are affected by Alpha-gal have to be constantly vigilant about the ingredients they consume, because an allergic reaction can be severe and life-threatening; and  (7) As doctors are not required to report the number of patients suffering with Alpha-gal, the true number of affected individuals is unknown.    (b) The purpose of this subchapter is to:  (1) Promote awareness and encourage efforts to treat Alpha-gal in the state; and  (2) Ensure food safety for individuals with Alpha-gal allergies through better food labeling.    (c) This section shall expire on December 31, 2018.
AR Code § 20-15-2202 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 22 - Task Force on Alpha-gal|§ 20-15-2202. Task Force on Alpha-gal — Creation

 (a) The Task Force on Alpha-gal is created.  (b) The task force shall be composed of the following seventeen (17) members:  (1) One (1) senator appointed by the President Pro Tempore of the Senate;  (2) Two (2) members of the House of Representatives appointed by the Speaker of the House of Representatives;  (3) The Director of the Department of Health or his or her designee, serving as an ex officio, nonvoting member;  (4) The Insurance Commissioner or his or her designee, serving as an ex officio, nonvoting member;  (5) The Secretary of the Arkansas Agriculture Department or his or her designee, serving as an ex officio, nonvoting member;  (6) Three (3) members who are employed by the Department of Health and designated by the Director of the Department of Health;  (7) One (1) member who is designated by the Arkansas Hospitality Association, Inc.;  (8) One (1) member who is designated by the Arkansas State Board of Nursing;  (9) One (1) member who is designated by the Arkansas Pharmacist’s Association;  (10) One (1) member who is designated by the American Academy of Allergy, Asthma and Immunology;  (11) One (1) member who is designated by the American College of Allergy, Asthma and Immunology;  (12) Two (2) members who are designated by the Division of Agriculture of the University of Arkansas; and  (13) One (1) member who is a patient with a diagnosis of Alpha-gal allergies and who is appointed by the Speaker of the House of Representatives.    (c) The terms of the legislative members of the task force shall expire on December 31, 2018.  (d) Nonlegislative members shall serve at the pleasure of the organizations they represent.  (e) Vacancies on the task force shall be filled in the same manner as provided for the initial appointment.  (f) The chair shall be one (1) of the legislative members of the task force and shall be selected by the legislative members of the task force.  (g) The task force shall meet as often as is deemed necessary by the chair.  (h) The members of the task force shall serve without compensation and shall not receive per diem, mileage, or stipends.  (i) The task force shall receive staff support from the Bureau of Legislative Research.  (j) This section shall expire on December 31, 2018.
AR Code § 20-15-2203 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 22 - Task Force on Alpha-gal|§ 20-15-2203. Task Force on Alpha-gal — Duties

 (a) The Task Force on Alpha-gal shall make recommendations designed to improve and increase knowledge and treatment throughout the state for Alpha-gal, especially for emergency room healthcare professionals.  (b) The task force shall submit a report to the Legislative Council, the Senate Committee on Public Health, Welfare, and Labor, and the House Committee on Public Health, Welfare, and Labor no later than October 1 annually.  (c) This section shall expire on December 31, 2018.
AR Code § 20-15-2301 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2301. Maternal Mortality Review Committee

 (a)  (1) The Department of Health shall establish the Maternal Mortality Review Committee to review maternal deaths and to develop strategies for the prevention of maternal deaths.  (2) The committee shall be multidisciplinary and composed of members as deemed appropriate by the department.    (b) The department may contract with an external organization to assist in collecting, analyzing, and disseminating maternal mortality information, organizing and convening meetings of the committee, and other tasks as may be incident to these activities, including providing the necessary data, information, and resources to ensure successful completion of the ongoing review required by this section.
AR Code § 20-15-2302 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2302. Powers and duties

 The Maternal Mortality Review Committee shall:   (1) Review pregnancy-associated deaths or deaths of women with indication of pregnancy up to three hundred sixty-five (365) days after the end of pregnancy, regardless of cause, to identify the factors contributing to these deaths;  (2) Identify maternal death cases;  (3) Review medical records and other relevant data;  (4) Contact family members and other affected or involved persons to collect additional relevant data;  (5) Consult with relevant experts to evaluate the records and data;  (6) Make determinations regarding the preventability of maternal deaths;  (7) Develop recommendations for the prevention of maternal deaths, including public health and clinical interventions that may reduce these deaths and improve systems of care; and  (8) Disseminate findings and recommendations to policy makers, healthcare providers, healthcare facilities, and the general public.
AR Code § 20-15-2303 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2303. Access to records

 (a) Healthcare providers, healthcare facilities, and pharmacies shall provide reasonable access to the Maternal Mortality Review Committee to all relevant medical records associated with a case under review by the committee.  (b) A healthcare provider, healthcare facility, or pharmacy providing access to medical records as described by subsection (a) of this section is not liable for civil damages or subject to any criminal or disciplinary action for good faith efforts in providing such records.
AR Code § 20-15-2304 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2304. Confidentiality

 (a)  (1) Information, records, reports, statements, notes, memoranda, or other data collected under this subchapter are not admissible as evidence in any action of any kind in any court or before any other tribunal, board, agency, or person.  (2) Information, records, reports, statements, notes, memoranda, or other data collected under this subchapter shall not be exhibited or disclosed in any way, in whole or in part, by any officer or representative of the Department of Health or any other person, except as necessary for the purpose of furthering the review of the Maternal Mortality Review Committee of the case to which they relate.  (3) A person participating in a review shall not disclose, in any manner, the information so obtained except in strict conformity with such review project.    (b) All information, records of interviews, written reports, statements, notes, memoranda, or other data obtained by the department, the committee, and other persons, agencies, or organizations so authorized by the department under this subchapter are confidential.  (c)  (1) All proceedings and activities of the committee under this subchapter, opinions of members of the committee formed as a result of such proceedings and activities, and records obtained, created, or maintained pursuant to this subchapter, including records of interviews, written reports, and statements procured by the department or any other person, agency, or organization acting jointly or under contract with the department in connection with the requirements of this subchapter, are confidential and are not subject to the Freedom of Information Act of 1967, § 25-19-101 et seq., relating to open meetings, subject to subpoena, discovery, or introduction into evidence in any civil or criminal proceeding.  (2) However, this subchapter does not limit or restrict the right to discover or use in any civil or criminal proceeding anything that is available from another source and entirely independent of the committee's proceedings.    (d)  (1) Members of the committee shall not be questioned in any civil or criminal proceeding regarding the information presented in or opinions formed as a result of a meeting or communication of the committee.  (2) This subchapter does not prevent a member of the committee from testifying to information obtained independently of the committee or which is public information.
AR Code § 20-15-2305 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2305. Disclosure

 Disclosure of protected health information is allowed for public health, safety, and law enforcement purposes, and providing case information on maternal deaths for review by the Maternal Mortality Review Committee is not a violation of the Health Insurance Portability and Accountability Act of 1996.
AR Code § 20-15-2306 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2306. Immunity from liability

 State, local, or regional committee members are immune from civil and criminal liability in connection with their good faith participation in the maternal death review and all activities related to a review with the Maternal Mortality Review Committee.
AR Code § 20-15-2307 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 23 - Maternal Mortality Review Committee|§ 20-15-2307. Reporting

 (a) Beginning in 2020, the Maternal Mortality Review Committee shall file a written report on the number and causes of maternal deaths and its recommendations on or before December 31 of each year to:  (1) The Senate Committee on Public Health, Welfare, and Labor;  (2) The House Committee on Public Health, Welfare, and Labor; and  (3) The Legislative Council.    (b) The report shall include:  (1) The findings and recommendations of the Maternal Mortality Review Committee; and  (2) An analysis of factual information obtained from the review of the maternal death investigation reports and any local or regional review panels that do not violate the confidentiality provisions under this subchapter.    (c) The report shall include only aggregate data and shall not identify a particular facility or provider.
AR Code § 20-15-2401 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 24 - Maternal and Perinatal Outcomes Quality Review Committee|§ 20-15-2401. Maternal and Perinatal Outcomes Quality Review Committee

 (a)  (1) The Department of Health shall establish the Maternal and Perinatal Outcomes Quality Review Committee to review data on births and to develop strategies for improving birth outcomes.  (2) The committee shall be multidisciplinary and composed of members as deemed appropriate by the department.    (b) The department may contract with an external organization to assist in collecting, analyzing, and disseminating maternal mortality information, organizing and convening meetings of the committee, and other tasks as may be incident to these activities, including providing the necessary data, information, and resources to ensure successful completion of the ongoing review required by this section.
AR Code § 20-15-2402 (2020)
2020 Arkansas Code|Title 20 - Public Health and Welfare|Subtitle 2 - Health and Safety|Chapter 15 - Disease and Disease Prevention Generally|Subchapter 24 - Maternal and Perinatal Outcomes Quality Review Committee|§ 20-15-2402. Powers and duties

 The Maternal and Perinatal Outcomes Quality Review Committee shall:   (1) Create a unified message and strategy that builds on best practices;  (2) Develop clear measurements to evaluate targeted outreach, progress, and return on investment;  (3) Develop recommendations for levels of care by establishing systems designating where infants are born or transferred according to the level of care they need at birth;  (4) Create a system of continuous quality improvement that will include the ability of designated and nondesignated hospitals to compare performance to peer facilities;  (5) Create a collaborative framework, in addition to quality improvement for birthing hospitals that will allow for better outcomes, better overall long-term care, and decreased cost of care; and  (6) Disseminate findings and recommendations to policy makers, healthcare providers, healthcare facilities, and the general public.